Tonix Pharmaceuticals/$TNXP
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Tonix Pharmaceuticals
Tonix Pharmaceuticals Holding Corp is a fully-integrated biopharmaceutical company commercializing and developing therapies for central nervous system (CNS) disorders, immunology, infectious diseases, and rare diseases. Its portfolio consists of commercial, development and discovery-stage programs, TONMYA, an approved treatment for fibromyalgia, as well as marketed acute migraine products Zembrace SymTouch and Tosymra. The company is conducting clinical trials to evaluate TONMYA for additional indications such as depressive disorder and acute stress disorder. It is also advancing a pipeline of immunology programs, including monoclonal antibody TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for the prevention of kidney transplant rejection.
Ticker
$TNXP
Sector
Primary listing
Employees
142
Headquarters
Website
TNXP Metrics
BasicAdvanced
$185m
-
-$14.10
1.69
-
Price and volume
Market cap
$185m
Beta
1.69
52-week high
$69.97
52-week low
$10.03
Average daily volume
517k
Financial strength
Current ratio
6.988
Quick ratio
6.569
Long term debt to equity
0.497
Total debt to equity
0.568
Interest coverage (TTM)
-1,698.72%
Profitability
EBITDA (TTM)
-149.199
Gross margin (TTM)
58.56%
Net profit margin (TTM)
-839.52%
Operating margin (TTM)
-861.16%
Revenue per employee (TTM)
$120,000
Management effectiveness
Return on assets (TTM)
-41.92%
Return on equity (TTM)
-72.33%
Valuation
Price to revenue (TTM)
6.927
Price to book
0.73
Price to tangible book (TTM)
0.73
Price to free cash flow (TTM)
-0.931
Free cash flow yield (TTM)
-107.43%
Free cash flow per share (TTM)
-12.494
Growth
Revenue change (TTM)
74.84%
Earnings per share change (TTM)
-76.38%
What the Analysts think about TNXP
Analyst ratings (Buy, Hold, Sell) for Tonix Pharmaceuticals stock.
TNXP Financial Performance
Revenues and expenses
TNXP Earnings Performance
Company profitability
TNXP News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs